The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Nontuberculous pulmonary mycobacterial infection/superinfection
Publications
Park DW, Kim YJ, Sung YK, Chung SJ, Yeo Y, Park TS, Lee H, Moon JY, Kim SH, Kim TH, Yoon HJ, Sohn JW
TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area.
Scientific reports 2022 Mar 07;12;4003 — 2022 Mar 07 — 4003
Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-? inhibitor: a case report.
BMC infectious diseases 2014 Feb 28;14;114 — 2014 Feb 28 — 114
Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ
Mycobacterial diseases and antitumour necrosis factor therapy in USA.
Annals of the rheumatic diseases 2013 Jan;72;37-42 — 2013 Jan — 37-42
Rapid growing mycobacteria and TNF-? blockers: case report of a fatal lung infection with Mycobacterium abscessus in a patient treated with infliximab, and literature review.
Clinical and experimental rheumatology 2011 Jul-Aug;29;705-7 — 2011 Jul-Aug — 705-7
Nontuberculous mycobacterial lung disease.
Current opinion in infectious diseases 2010 Apr;23;185-90 — 2010 Apr — 185-90